Drugmaker Bayer Healthcare will have to continue to defend itself against 20-year old claims it fraudulently marketed its cholesterol drug Baycol.
Whistleblower Laurie Simpson alleged the drugmaker fraudulently induced the Department of Defense to purchase more than $11 million worth of Baycol (cerivastatin) by misrepresenting its effectiveness and risks. Simpson is a former Baycol marketing manager.
It’s not uncommon for False Claims Act litigation like the Baycol case to drag on for years. Simpson filed her FCA case against Bayer almost exactly 18 years ago and many of the claims in the suit date back even farther. The FCA is ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.